Your session is about to expire
What is Emcyt
EstramustineThe Generic name of this drug
Treatment SummaryEstramustine is a medication that combines nitrogen mustard with the hormone estradiol. It is primarily used to treat prostate cancer and can also help protect against radiation.
Emcytis the brand name
Emcyt Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Emcyt
Estramustine
1992
1
Approved as Treatment by the FDA
Estramustine, otherwise known as Emcyt, is approved by the FDA for 1 uses such as Metastatic Hormone-Refractory Prostate Cancer .Metastatic Hormone-Refractory Prostate Cancer
Effectiveness
How Emcyt Affects PatientsEstramustine is a medicine used to treat prostate cancer that has spread to other parts of the body or is progressing. It is a combination of estradiol and nitrogen mustard, which becomes activated in the body and causes damage to rapidly dividing cancer cells. This damage leads to cell death, which can shrink the size of the tumor.
How Emcyt works in the bodyEstramustine has two key components: an estrogen and a nitrogen mustard. The nitrogen mustard part is a powerful alkylating agent, meaning it can attach to and damage DNA strands. This causes cells to die, and also helps the drug bind to active estrogen receptors. As a result, estramustine can target cancer cells more effectively.
When to interrupt dosage
The proposed measure of Emcyt is subject to the diagnosed situation. The amount of dosage is contingent upon the administration technique (e.g. Oral or Capsule - Oral) detailed in the table below.Condition
Dosage
Administration
Metastatic Hormone-Refractory Prostate Cancer
140.0 mg,
, Oral, Capsule, Capsule - Oral
Warnings
Emcyt ContraindicationsCondition
Risk Level
Notes
Thromboembolism
Do Not Combine
active thrombophlebitis
Do Not Combine
Common Emcyt Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Estramustine is combined with Acteoside.
Emcyt Novel Uses: Which Conditions Have a Clinical Trial Featuring Emcyt?
88 active trials are underway to assess the potential of Emcyt to provide therapeutic benefits for patients with Prostate Cancer.Condition
Clinical Trials
Trial Phases
Metastatic Hormone-Refractory Prostate Cancer
87 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Emcyt Reviews: What are patients saying about Emcyt?
4.7Patient Review
1/2/2008 I was amazed at how well this worked for my hormone independent prostate cancer. My PSA levels decreased from 10 to 4.8 in just 15 days of treatment with six capsules per day. In the following 30 days, it decreased again to 3.5.
Patient Q&A Section about emcyt
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What does Emcyt do?
"Emcyt is a prescription medication used to treat symptoms of prostate cancer. It may be used alone or with other medications. Emcyt belongs to a class of drugs called Antineoplastics, Hormones."
Answered by AI
How is Estramustine administered?
"To take estramustine, swallow it whole with water 3 to 4 times a day, at least one hour before or two hours after meals. You can take it at around the same times every day. Milk, milk products, and foods that contain calcium can make it harder for your body to absorb estramustine, so avoid them when taking this medication."
Answered by AI